Avalyn Pharma (AVLN)

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

A(z) Avalyn Pharma Inc. Common Stock (AVLN) részvény mai árfolyama 28,37 $, ami +5,80% elmozdulást tükröz a piac nyitása óta. A vállalat piaci kapitalizációja jelenleg 1,19 Mrd $, a napi kereskedési volumen pedig 42,75 E $ részvény. A befektetők számára, akik az ártendenciákat követik, a(z) Avalyn Pharma Inc. Common Stock-részvény 26,69 $–28,95 $ tartományban mozgott a mai napon. A korábbi záró ár 26,82 $ volt.

Készen állsz? Kövesd az alábbi lépéseket, vagy olvasd el útmutatónkat a(z) hogyan vásárolj Avalyn Pharma részvényt a Krakenen, kezdve 10 dollárral.